In a major win for HIV advocates, Gilead Sciences has reversed course on plans to raise prices for its HIV medications sold through state AIDS Drug Assistance Programs, or ADAPs. The company’s initial plan to impose high single-digit price hikes would have gutted these programs, which provide life-saving treatment for more than 110,000 low-income Americans living with HIV. The reversal follows intense pressure from the AIDS Healthcare Foundation and more than 100 organizations nationwide.
In a letter to Gilead CEO Daniel O’Day, they urged the company to halt its proposed hikes. ADAPs are a national safety net for people who can’t afford medication, and advocates warned that any increase could mean fewer prescriptions for those most in need. Critics say the move fits a pattern under O’Day’s leadership—prioritizing profit over access. For now, HIV advocates are celebrating a rare victory in the ongoing fight for affordable treatment.
